Histone demethylase lysine demethylase 5B in development and cancer

Mengjiao Han; Wenxia Xu; Pu Cheng; Hongchuan Jin; Xian Wang

doi:10.18632/oncotarget.13858

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Reviews:

Histone demethylase lysine demethylase 5B in development and cancer

Mengjiao Han, Wenxia Xu, Pu Cheng, Hongchuan Jin and Xian Wang _

PDF | HTML | How to cite

Oncotarget. 2017; 8:8980-8991. https://doi.org/10.18632/oncotarget.13858

Metrics: PDF 3543 views | HTML 5581 views | ?

Abstract

Mengjiao Han1, Wenxia Xu1, Pu Cheng2, Hongchuan Jin1, Xian Wang1

1Department of Medical Oncology, Key Laboratory of Biotherapy in Zhejiang, Sir Runrun Shaw Hospital, Medical School of Zhejiang University, China

2Department of Surgical Oncology, Key Laboratory of Cancer Prevention & Intervention, National Ministry of Education, Provincial Key Laboratory of Molecular Biology in Medical Sciences, Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, China

Correspondence to:

Xian Wang, email: [email protected]

Keywords: histone methylation, demethylases, KDM5B

Received: September 12, 2016 Accepted: November 08, 2016 Published: December 10, 2016

ABSTRACT

Histone methylation is one of the most important chromatin posttranslational modifications. It has a range of influences on nuclear functions including epigenetic inheritance, transcriptional regulation and the maintenance of genome integrity. Changes in histone methylation status take part in various physiological and pathological processes. KDM5B (lysine demethylase 5B, also called JARID1B or PLU-1) encodes the histone H3 lysine4 (H3K4) demethylase and exhibits a strong transcriptional repression activity. KDM5B plays a role in cell differentiation, stem cell self-renewal and other developmental progresses. Recent studies showed that KDM5B expression was increased in breast, bladder, lung, prostate and many other tumors and promotes tumor initiation, invasion and metastasis. Given its association with tumor progression and prognosis of cancer patients, KDM5B was proposed to be a novel target for the prevention and treatment of human cancers. In this review, we will summarize recent advances in our understanding of the regulation and function of KDM5B in development and cancer.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 13858

Publication Alerts

Reviews:

Histone demethylase lysine demethylase 5B in development and cancer

Abstract